BioSpace News Archive

Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has successfully closed a non-brokered private placement offering of units.

CervoMed Inc. today announced that Company’s Management will provide a corporate update at the Emerging Growth Conference 67, to be held virtually from February 7-8, 2024.

Mesa Laboratories, Inc. today announced results for its third fiscal quarter (“3Q24”) ended December 31, 2023.

Oryzon Genomics, S.A. announced today that its management will give an update on corporate progress at several international events in February and March.

Stryker (NYSE:SYK) will participate in Citi’s 2024 Unplugged Medtech and Life Sciences Access Day on Thursday, February 29, 2024 at Citigroup Headquarters, New York, New York.

Vaxart, Inc. announced the publication of preclinical non-human primate data demonstrating the potential of its COVID-19 vaccine to protect against multiple SARS-CoV-2 variants of concern (VOC)s.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, highlighted recent successes across the Company’s immunotherapy portfolio and provided updates on multiple upcoming milestones.

Aclarion, Inc. announced that it has completed several recent financing transactions that have significantly reduced debt and increased available cash.

Inspire Medical Systems, Inc. announced the retirement of Marilyn Carlson Nelson as Chair of its Board of Directors and the appointment of Chief Executive Officer Timothy P. Herbert to the additional role of Board Chair, to be effective at the conclusion of the Company’s Annual Meeting of Stockholders scheduled to occur on May 2, 2024.

iRegene Therapeutics Co., Ltd (iRegene) recently announced that NouvNeu001, the company’s first innovative product, has completed the dosing for its first patient at Beijing Hospital, and the patient has also successfully concluded the observation period.